Outcomes from RESONATE Trial in Relapsed CLL

Outcomes from RESONATE Trial in Relapsed CLL

obr

2 months
67 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Paul M.Barr MD Associate Professor of Medicine at Wilmot Cancer Institute explains the results found of the RESONATE Trial that was evaluating ibrutinib versus ofatumumab in relapsed chronic lymphocytic leukemia (CLL).
Up Next Autoplay